Medicine Introduction Center

Posts Tagged ‘2016’

The Future Of Cosmetic Medical Device Market By 2016 – the market to regain a positive growth of
GBI

Research new report, “The future of the aesthetic device market in 2016 – the market to regain positive growth,” provides key data, information and analysis on the global aesthetic devices market, a key segment in the industry medical equipment. This report provides medical device market outlook, competitive landscape and market trends information in three categories of aesthetic medical device market – Laser Aesthetics and power devices, facial and breast implants. The report provides an overview of key trends affecting this category, and analytical content key in the dynamics of the market. The report also examines the competitive landscape, key pipeline products and technology offerings.

This report builds on data and information from proprietary databases, primary and secondary research and analysis of the home by GBI investigation team of industry experts. Scope

• Key geographies including the U.S. (United States), Japan, France, the United Kingdom (UK), Germany, Italy and Spain
• Size of global market and company data shared by three categories aesthetic medical device market -. Cosmetic lasers and energy devices, facial and breast implants.
• annualized market data revenues for 2009, forecasting the progress of 7 years to 2016. Update company stock data for 2009.
• Qualitative analysis of key market trends, market drivers and restrictions on categories and segments.
Company profiles • competitive landscape and key. Major players covered include Allergan, Mentor Corporation, Sientra, Medicor, Cynosure, Lumenis, Syneron, Candela, Palomar Medical, Cutera, Solta Medicine, and medical QMed Bioform.
• Insert conduit products and technologies expected to reach the global market for aesthetic medical devices in the near future.

Reasons to buy • Develop business strategies through an understanding of trends and developments that are driving the market for aesthetic medical devices worldwide.
• Design and development of its product development, marketing and sales strategies.
• Take advantage of opportunities for mergers and acquisitions by identifying market players with the most innovative pipeline.
• Develop market entry and market expansion strategies.
• Identify key players in a better position to exploit emerging market opportunities.
• Exploit the granting of licenses and licensing opportunities out by identifying products, most likely to ensure a solid return.
• What is the next huge thing in the medical aesthetic devices market landscape? – Identify, know and capitalize
• Make more informed business decisions after thorough and exhaustive analysis of the market for aesthetic medical devices and the factors that determine

1 Table of Contents br <. />
1.1 List of Tables 7 1.2 List

Figures 8 2 Introduction 9 2.1 Orientation Research
GBI 9

3 Aesthetics Medical Devices World: Market characterization 10 3.1 Market
Global Cosmetic Medical Devices, Forecasts Revenue ($ million), from 2009 to 2016 10 3.2
Aesthetics Medical Devices, Market Trends 10 3.3
Aesthetic Medical Device, 11 br /> market

Market 12 3.4 Global Medical Aesthetic devices, the key actions of the company, 2009 12

4 Global Medical Device Market Aesthetics: Category Analysis and Forecasts 14 4.1
Aesthetic Laser power devices 14 4.1.1
Global Cosmetic Laser and output devices energy, estimated revenue ($ m), from 2009 to 2016 14 4.1.2
Cosmetic lasers and energy devices: key market trends 4.1.3 15
Aesthetic Laser energy devices: Market Dynamics 16 4.1.4
Global Aesthetic Laser Market and Energy Devices, key company share (%) 2009 18
4.2 18 breast implants
4.2.1 Global Market breast implants, revenue forecast ($ m), from 2009 to 2016 19 4.2.2
breast implants: key market trends
19 4.2. 3 Breast implants: the dynamics of the market 20 4.2.4
silicone breast implants from the market, revenue forecasts ($ m), from 2009 to 2016 20
4.2.5 The saline breast implants market, revenue forecasts (million dollars) from 2009 to 2016 21 4.2.6 Global Market
breast implants, the key actions of the company (%) 2009 22 Facial Aesthetics
4.3 22
4.3.1 Global Market of Facial Aesthetics, the estimated revenue ($ m), from 2009 to 2016 23 4.3.2
Facial Aesthetics: key market trends 4.3.3 23
Facial Aesthetics: Market Dynamics 4.3.4 Market 24
Global Facial Aesthetics, the company’s key actions (%) 2009 24 4.3.5
hyaluronic acid, revenue forecasts (million dollars), 2009 – 2016 25
4.3.6 Polymer Particles & Dust (PPF), Forecasts of Revenue (million dollars) from 2009 to 2016 26 4.3.7
collagen products, revenue forecasts (U.S. $ million ), from 2009 to 2016 27

5 Global Medical Device Market Aesthetics: Country Analysis and Forecasts 28 5.1 The U.S.
Aesthetic Medical Devices Market 28 5.1.1 The U.S.
Aesthetic Laser devices and energy production, income ($ m), from 2009 to 2016 28 5.1.2 The U.S.
Aesthetic Laser energy production devices, the key actions of the company (%) 2009 29 5.1.3 The U.S.
Breast implants market revenues ($ m), from 2009 to 2016 30 5.1.4 The U.S.
Breast implants market, the key actions of the company (%) 2009 31
5.1.5 The U.S. market Facial Aesthetics, income ($ m), from 2009 to 2016 32
5.1.6 U.S. Market Facial Aesthetics, the company’s key actions (%) 2009 33
Market 5.2 The Japanese Aesthetic Medical Devices 33 5.2.1
Japanese aesthetic laser devices and energy production, income ($ m), from 2009 to 2016 34 5.2.2
Japanese Aesthetic Laser and market power devices, the key actions of the company (%) 2009 34 5.2.3
Japanese breast implants market revenues ($ m), from 2009 to 2016 35 5.2.4
breast implants Japanese market, the key actions of the company (%) 2009 36
5.2.5 Market Japan Facial Aesthetics, income ($ m), from 2009 to 2016 36 5.2.6 Japanese market
Facial Aesthetics, the company’s key actions (%) 2009 37 5.3
European Medical Market Aesthetic devices 37 5.3.1
European and aesthetic laser devices for energy production, income ($ m), from 2009 to 2016 38 5.3.2
European Aesthetic Laser energy production devices, the key actions of the company (%) 2009 39 5.3.3
breast implants European Market 40 5.3.4
breast implants market in Europe, the key actions of the company ( %), 2009 42
5.3.5 European Market for Facial Aesthetics
3.5 0.6 43 European Facial Aesthetic Market, the company’s key actions (%) 2009 46

6 Global Medical Device Market Aesthetic: Competitive assessment 47 6.1 Lumenis Ltd.
47

6.1.1 Products 47 6.2 47 Candela Corporation Finance 6.2.1
47

6.2.2 Products 48 6.3 Cynosure, Inc 48
48
Finance 6.3.1 3.6 0.2 6.3.3 Products 49
Cynosure Signs an Association Agreement with Unilever 49 6.4 Syneron Medical
49
50
6.4.1 Finance 6.4.2 Products 50 4.6 0.3
medical Syneron Medical to buy 51
Primaeva 6.4.4 Syneron Candela Corporation to combine 51
6.5 Cutera, Inc. 52
6.5.1 Finance 6.5.2 Products 52
52
Palomar Technologies 6.6 53
53
6.6.1 Finance 6.6.2 Products 53 6.6.3
Palomar Medical Technologies and Johnson & Johnson Complete Agreement
6.6 0.4 54 Palomar Medical Technologies Terminates Agreement with Q-Med 54
6.7 Mentor Corporation 54

6.7.1 Products 55 6.7.2 Johnson & Johnson buys Mentor Corporation 55
6.8 Allergan, Inc. 56 6.8.1
Finance 56 6.8.2 Products 57

QMed AB 6.9 57 57

6.9.1 Finance 6.9.2 Products 58
6.10 Sientra, Inc 58
6.10.1 Products 6.11 59
BioForm Medical, Inc. 59
59
6.11.1 Finance 6.11.2 Products 6.11.3 60
Merz Pharma buys BioForm Medical 60

7 devices Aesthetic Medicine World Market: Product Pipeline Analysis 62 7.1
energy Cosmetic and Laser devices
7.1.1 SANUWAVE 62: 63 evoPACE Cellulite
Asclepion Laser Technologies 7.1.2 Effect 7.1.3 Mediostar 63
Candela Corporation: Pneumatic Skin fattening (PSF) to tone the skin 63
7.1.4 Medicis Pharmaceutical Corporation: LipoSonix System 64
7.1.5 Sonovia limited: Ultrasound technology SonoRx 64
7.1.6 Medixsysteme: 64
7.1.7 SpaShape Medixsysteme: Ultracontour-U.Lift
7.2 64 breast implants 7.2.1 65-
Alure Medical: Alure Refine 65
7.2.2 Mesynthes Ltd: Unit 65 Endoform breast Allergan
7.2.3: Style Natrelle
7.2 410 65 .4 AirXpanders: patient-activated devices controlled expansion Sientra 66
7.2.5: Improve Silimed 66
7.2.6 Sientra: Silimed soft silicone gel implants Round 66
Facial Aesthetics 7.3
7.3.1 Contura 67 International: 67
7.3.2 Aquamid Serica Technologies: Silk Eplica 67
Evera Medical 7.3.3: FulFil lip implant cosmetic Increase 67
7.3.4 QMed: Macrolane 68
7.3.5 Mentor Corporation: Puragen 68
7.3.6 Allergan: Volume 68

8 Appendix 69 8.1 Definitions 69
8.1.1 Aesthetic Laser power devices 69
Breast Implants 69 8.1.2 8.1.3 Facial Aesthetics
69
69
8.2 Acronyms 8.3 Research Methodology 69
8.3.1 Secondary Research 70 8.3.2 Primary Research

8.3.3 Models 70 71 71

8.3.4 Forecasts 8.3.5 Expert Panels 71
8.4 Contact Us 71 8.5 Disclaimer 72

1.1 List of Tables Table 1
: Medical Device Market Aesthetics, total revenue, total ($ million) from 2009 to 2016 10
Table 2: Market Aesthetics Medical Devices, Global, joint stock company (%) 2009 13
Table 3: Aesthetic Laser and devices for energy, total income, general ($ m), 2009-2016

15 Table 4: Major Medical, number of practitioners, USA, 2009 17
Table 5: Aesthetic Laser Device energy production and World Share, the company (%) 2009 18
Table 6: Breast implants market, the overall revenues, general ($ m), from 2009 to 2016 Table 19
7: The silicone breast implant market, Global, ($ m), from 2009 to 2016
21 Table 8: saline breast implants Global Market, the total income ($ m), 2009 – 2016
21 Table 9: Breast implants Global Market Share of the company (%) 2009 22
Table 10: Facial Aesthetic Market, the overall revenues, general ($ m), 2009-2016
23 Table 11: Facial Aesthetic Market, Global Action, the company (%) 2009 24
Table 12: Market hyaluronic acid, the overall revenues, general ( $ m), from 2009 to 2016 25
Table 13: Particle and Polymer Fillers market, the overall revenues, general ($ m), from 2009 to 2016
26 Table 14: Market Product collagen, the overall revenues, general ($ m), 2009-2016 27
Table 15: Aesthetic Laser energy production devices, the U.S., total revenue ($ m), 2009

2016 28 Table 16: Cosmetic Laser and devices for energy, U.S., Company Share (%) 2009 29
Table 17: Market for breast implants, U.S. , total revenue ($ m), from 2009 to 2016
30 Table 18: Breast Implants Market, U.S., Company Share (%) 2009 31
Table 19: Cosmetic Market Facial, USA, total revenue ($ m), 2009-2016
32 Table 20: Facial Aesthetic Market, U.S., Company Share (%) 2009 33 Table 21
: Cosmetic Laser and power devices market, Japan, the total revenue ($ m), 2009-2016

34 Table 22: Cosmetic Laser and devices for energy, Japan, Company Share (% )
2009 35 Table 23: Breast implants market, Japan, the total revenue ($ m), from 2009 to 2016
35 Table 24: Breast Implant Market, Japan, Company Share (%) 2009 36
Table 25: Facial Aesthetic Market, Japan, the total revenue ($ m), from 2009 to 2016
37 Table 26: Facial Aesthetic Market, Japan, Company Share (%) 2009 37
Table 27: Aesthetic Laser power devices market, Europe, total revenue ($ m), 2009-2016
38 Table 28: Aesthetic Laser energy production devices , Europe and shares the company (%) 2009 39
Table 29: Market silicone breast implants, Europe, total revenue ($ m), from 2009 to 2016 40
Table 30: Market saline breast implants, Europe, total revenue ($ m), from 2009 to 2016
41 Table 31: Breast Implant Market, Europe, Company Share (%) 2009 42 Table 32
: hyaluronic acid market, Europe, total revenue ($ m), from 2009 to 2016
43 Table 33: Market polymer particles and dust, Europe, General Revenue (million dollars) from 2009 to 2016 44
Table 34: Market collagen products, Europe, total revenue ($ m), from 2009 to 2016
45 Table 35: Facial Aesthetic Market, Europe and shares the company (%), 2009
46 Table 36: Lumenis, products, applications, features and benefits,
2010 47 Table 37: Candela Corporation, Products, Applications Features and Benefits, 2010 48 Table 38
: Cynosure, Products applications, features and benefits
2010 49 Table 39: Cynosure Signs an Association Agreement with Unilever,
2009 49 Table 40: Syneron Medical, Products, applications, features and benefits, 2010 50
Table 41: Syneron Medical to buy Primaeva Medical
2009 51 Table 42: Syneron and combine Candela Corporation, 2009 51 Table 43
: Cutera, Products, Applications, Features and Benefits, 2010 52
Table 44: Palomar, products, applications, features and benefits
2010 53 Table 45: Mentor Corporation, products, applications, features and benefits
2010 55 Table 46: Johnson &, Johnson buys Mentor Corporation, 2009 55
Table 47: Allergan, products, applications, features and benefits
2010 57 Table 48: QMed, products, applications, features and benefits
2010 58 Table 49: Sientra, products, applications, features and benefits
2010 59 Table 50: BioForm Medical, products, applications, features and benefits of
2010 60 Table 51: Merz Pharma buys BioForm Medical, 2010 60
Table 52: Facial Aesthetics, new products, the 2009 World
62 Table 53: Breast implants, new products, World
2009 65 Table 54: Facial Aesthetics, new products, Global, 2009 67

1.2 List of Figures Figure 1
: Medical Device Market Aesthetics, total revenue, total ($ million) from 2009 to 2016 10
Figure 2: Aesthetics Market Medical Devices, Global, joint stock company (%) 2009 12
Figure 3: Laser Aesthetics and energy production devices, the overall revenues, general ($ m), 2009-2016
14
Figure 4: Aesthetic Laser and energy production devices and World Share, the company (%) 2009 18
Figure 5: The market for breast implants, the overall revenues, general ($ m) from 2009 to 2016 19
Figure 6: Silicone breast implants market, the overall revenues, general ($ m), from 2009 to 2016 20
Figure 7: Market saline breast implants , the overall revenues, general ($ m), from 2009 to 2016 21
Figure 8: breast implant market, Global, joint stock company (%) 2009 22
Figure 9: Facial Aesthetic Market , the overall revenues, general ($ m), from 2009 to 2016 23
Figure 10: Facial Aesthetic Market, Global, Company Share (%) 2009 24
Figure 11: Market hyaluronic acid , the overall revenues, general ($ m), 2009-2016
25 Figure 12: Particles and polymer powder market, the overall revenues, general ($ million), from 2009 to 2016 26 Figure 13
: Market for collagen, total revenue, general ($ m), from 2009 to 2016
27 Figure 14: Laser Aesthetics and energy production devices, the U.S., total revenue ($ million ), from 2009 to 2016 28
Figure 15: Cosmetic Laser and Energy Market devices, U.S., Company Share (%) 2009 29
Figure 16: The breast implant market, U.S. ., total revenue ($ m), 2009-2016
30 Figure 17: The breast implant market, the U.S., Company Share (%) 2009 31
Figure 18: Market Facial Aesthetics, the U.S., total revenue ($ m), from 2009 to 2016 32
Figure 19: Facial Aesthetic Market, U.S., Company Share (%) 2009 33 Figure
20: Aesthetic Laser energy production devices, Japan, the total revenue ($ m),
2009 to 2016 34
Figure 21: Laser Aesthetics and devices for energy, Japan, Company Share (%) 2009 34
Figure 22: Breast Implant Market, Japan, the total revenue ($ m), 2009-2016
35 Figure 23: Breast Implant Market, Japan, Company Share ( %), 2009 36
Figure 24: Facial Aesthetic Market, Japan, the total revenue ($ m), from 2009 to 2016 36
Figure 25: Facial Aesthetic Market, Japan, Company Share (%) , 2009 37
Figure 26: Laser Aesthetics and energy production devices, Europe, total revenue ($ m), 2009-2016

38 Figure 27: Laser Aesthetics and devices Energy, Europe and shares the company (%) 2009 39
Figure 28: Market silicone breast implants, Europe, total revenue ($ m), from 2009 to 2016 40
Figure 29: The saline breast implant market, Europe, total revenue ($ m), from 2009 to 2016 41
Figure 30: Breast Implant Market, Europe and shares the company (%) 2009 42
Figure 31: hyaluronic acid market, Europe, total revenue ($ m), from 2009 to 2016 43
Figure 32: Market polymer particles and dust, Europe, total revenue ($ m), from 2009 to
2016 44 Figure 33: Market collagen products, revenues from Europe, general ($ m), from 2009 to 2016 45
Figure 34: Facial Aesthetic Market, Europe and shares the company (% )
2009 46 Figure 35: Research Methodology GBI 70

The industry analysis specialist’s new report on the pharmaceutical and healthcare sector, “Type 2 Diabetes – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global type 2 diabetes market. The report identifies the key trends shaping and driving the global type 2 diabetes market, a key segment within the pharma industry. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global type 2 diabetes sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts. ScopeThe scope of the report includes: – Annualized global type-2 diabetes therapeutics market revenues data from 2001 to 2009, forecast forward for 7 years to 2016. – Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan. – Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. Key classes of mechanisms of action include SGLT-2 inhibitors, 11â HSD inhibitors, CCR2 antagonists, selective inhibitors of fructose 1,6-bisphosphatase, immune modulators, cortisol synthesis Inhibitors, interleukin-1â antagonists, gastrin-releasing peptide (GRP) receptor agonists, GPR 119 agonists,TLR-4 receptor agonists, FXR antagonists and antisense drugs targeting glucagon receptor. – Analysis of the current and future market competition in the global type-2 diabetes therapeutics market. Key future market players covered are Hoffmann-La Roche, Novo Nordisk, Merck & Co. , Novartis Ag, Sanofi-aventis, Eli Lilly & Company and GlaxoSmithKline. – Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. – Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with type-2 diabetes market. More Information Please Click:http://www. aarkstore. com/reports/Type-2-Diabetes-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40631. htmlOr Call Us: 919272852585Visit Our Blog: http://blogs. aarkstore. com

The industry analysis specialist, has released a new report on the Pharmaceutical and Healthcare industry, “Type 1 Diabetes – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global type 1 diabetes market. The report identifies the key trends shaping and driving the global type 1 diabetes market, a key segment within the pharma industry. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global type 1 diabetes sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts. ScopeThe scope of the report includes: Annualized global type 1 diabetes market revenues data from 2000 to 2009, forecast forward for 7 years to 2016. Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan. Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Analysis of the current and future market competition in the global type 1 diabetes market. Key market players include Novo Nordsik, Eli Lilly, GlaxoSmithKline and Sanofi-aventis. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with type 1 diabetes. More Information Please Click:http://www. aarkstore. com/reports/Type-1-Diabetes-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40542. htmlOr Call Us: 919272852585Visit Our Blog: http://blogs. aarkstore. comKeywords: Diabetes, Drug, Type 1 Diabetes, Pipeline Analysis, Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies,  strategic competitor assessment, market characterization,  implications for future market, mechanism of action.

It is the industry analysis specialist’s new report, “Anti-Hypertension – Drug Pipeline Analysis and Market Forecasts to 2016″” is an essential source of information and analysis on the global anti-hypertension market, a key segment within the pharmaceutical and healthcare industry. This pharma report identifies the key trends shaping and driving the global anti-hypertension market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global anti-hypertension sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by  its team of industry experts. Scope The scope of the report includes: – Annualized global anti-hypertension market revenues data from 2001 to 2009, forecast forward for seven years to 2016. – Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan. – Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The first-in-class drugs act through new mechanisms of action such as eNOS (Endothelial Nitric Oxide Synthase) couplers, sodium-glucose transport 2 (SGLT2) inhibitors, endothelin antagonists, peroxisome proliferator-activated receptor (PPAR)-gamma agonists and cyclooxygenase-1 (COX-1) inhibitors. – Analysis of the current and future market competition in the global anti-hypertension market. Key future market-players covered are Novartis Ag, Merck & Co. Inc. , AstraZeneca, Takeda Pharmaceuticals, Daiichi Sankyo Co. Ltd, GlaxoSmithKline Plc, and Sanofi-Aventis. – Insightful reviews of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. – Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with anti-hypertension. For More Information Please Click:http://www. aarkstore. com/reports/Anti-hypertension-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-37973. html Or Call Us: 919272852585 Visit Our Blog: http://blogs. aarkstore. com

GlobalData forecasts the global candidiasis market to grow at 5. 9% annually for the next seven years to reach $2,386m by 2016. It was valued at $1,592m in 2009. This moderate growth will primarily be supported by an increase in the disease incidence rate and the launch of two promising pipeline molecules during the forecast period. The growth of the candidiasis market during the forecast period will not be much higher than the rate at which it grew between 2001 and 2009. This is primarily attributed to two reasons. First, the candidiasis market is dominated by generic products which generate less revenue per unit volume sold. Second, the pipeline of the candidiasis market is weak with a small number of molecules across different stages of development. But, the continued uptake of the currently marketed products and the launch of some of the late-stage pipeline molecules will sustain market growth during the forecast period.

For more information please click or add the below link to your browser:

http://www. globaldata. com/reportstore/Report. aspx?ID=Candidiasis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare

GlobalData’s analysis has found that the current competition in the candidiasis market is strong. The current candidiasis market landscape has more than 10 marketed products. The marketed products fall under three different classes: azoles, polyenes and echinocandins. Polyenes and azoles are some of the oldest classes of drugs being used in the treatment of different types of Candida infection. The drugs from these classes are quite successful in meeting the therapeutic needs of the market and have first rate efficacy and safety profiles. Moreover, these drugs are available in different dosage forms and have high patient compliance rates. Echinocandins are available in an intravenous dosage form and have medium to high efficacy in the treatment of serious Candida infections such as invasive candidiasis, esophageal candidiasis and systemic candidiasis. Furthermore, all the products are able to cure the Candida infection in most of the cases. Because the current treatment options offer high clinical and safety standards and successfully meet the market demands, the unmet need in the candidiasis market is low.

GlobalData, the industry analysis specialist, has released its latest report, “Candidiasis – Drug Pipeline Analysis and Market Forecasts to 2016″, which provides the key data, information and analysis on the candidiasis market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecast seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated with candidiasis, a competitive assessment, the product profiles of the major marketed products and the promising drugs in the pipeline, an overview of the discontinued projects, the implications for the future market competition, and the key players in the candidiasis market.

Visit our report store: http://www. globaldata. com/reportstore

GlobalData’s report, “Nonalcoholic Steatohepatitis (NASH)– Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global nonalcoholic steatohepatitis market. The report identifies the key trends shaping and driving the global nonalcoholic steatohepatitis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global nonalcoholic steatohepatitis sector. GlobalData estimated that the Nonalcoholic Steatohepatitis (NASH) market was worth $1. 8 billion in 2009. The major reason for the limited market revenues is that there is no approved drug for the treatment of NASH. NASH is an unrecognized cause of cryptogenic cirrhosis with emerging importance. It is a more aggressive form of NAFLD (Nonalcoholic Fatty Liver Disease), which often progresses to liver cirrhosis. The increased prevalence of diabetes, obesity and hyperlipidemia are considered to be vital causes of NASH. Antioxidants, anti-diabetic medications, anti-obesity medications and antihyperlipidemics are some of the off-mark products currently used by NASH patients. The modest growth forecast is primarily attributed to a weak pipeline landscape. Due to the fact that low diagnosis rates, low prescription rates and low treatment seeking rates continue to pose significant challenges for prospective market entrants, the market landscape in future is expected to remain static without any significant dynamism.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes: – Annualized global nonalcoholic steatohepatitis market revenue data from 2001 to 2009, forecast for seven years to 2016. – Key geographies covered in this report include the US (the United States), the UK (the United Kingdom), Italy, Spain, Germany, France and Japan. – Pipeline analysis data providing a split across the different phases of development by mechanism of action and emerging trends. The key classes of mechanism of action include dietary supplements, enzyme inhibitors, PPAR (peroxisome proliferator-activated receptor) gamma selective agonists, combination therapies, cholesterol Inhibitors, CB-1 cannabinoid receptor antagonists, angiotensin II receptor antagonists, lipid peroxidation inhibitors, glutathione enhancers and immunologic drugs. – Analysis of the current and future market competition in the global nonalcoholic steatohepatitis market. Key market players covered are Raptor Pharmaceuticals, Gilead Sciences, Axcan Pharma, Eli Lilly & Company and Enzo Biochem. – Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. – Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with NASH.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of the pipeline products and technologies and by identifying the companies with the most robust pipelines. – Develop business strategies by understanding the trends shaping and driving the global NASH market. – Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global NASH market in the future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolios and make effective counter-strategies to gain a competitive advantage. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. – What’s the next huge thing in the global NASH market landscape? – identify, know and capitalize.

TABLE OF CONTENTS

1 Table of contents 3 1. 1 List of Tables 5 1. 2 List of Figures 5

2 Nonalcoholic Steatohepatitis Market : Market Characterization 6 2. 1 Disease Overview 6 2. 2 Symptoms 7 2. 3 Diagnosis 7 2. 3. 1 Ultrasonography 7 2. 3. 2 Computed Tomography 8 2. 3. 3 Magnetic Resonance Imaging 8 2. 3. 4 Liver function tests 8 2. 3. 5 Liver Biopsy 8 2. 4 Treatment 8 2. 5 Epidemiology 9 2. 6 Prevention 10 2. 7 Nonalcoholic Steatohepatitis Disease Market Size 11 2. 8 Nonalcoholic Steatohepatitis Market Forecast and CAGR 12 2. 9 Drivers and Barriers for the Nonalcoholic Steatohepatitis Disease Market 13 2. 9. 1 Drivers for the NASH Market 13 2. 9. 2 Barriers for the NASH Market 14 2. 10 Opportunity and Unmet Need 15 2. 11 Key Takeaway 16

3 Nonalcoholic Steatohepatitis Market : Competitive Assessment 17 3. 1 Overview 17 3. 2 Strategic Competitor Assessment 17 3. 3 Product Profile for the Major Off-Mark Marketed Products in the Nonalcoholic Steatohepatitis Market 18 3. 3. 1 Antioxidants 18 3. 3. 2 Anti-diabetic Medications 19 3. 3. 3 Anti-obesity Medications 19 3. 3. 4 Antifibrotic Medications 19 3. 4 Key Takeaway 20

4 Nonalcoholic Steatohepatitis Market : Pipeline Assessment 21 4. 1 Overview 21 4. 2 Strategic Pipeline Assessment 21 4. 2. 1 Technology Trends Analytic Framework 21 4. 3 Nonalcoholic Steatohepatitis Therapeutics – Promising Drugs under Clinical Development 23 4. 4 Molecule Profile for Promising Drugs under Clinical Development 25 4. 4. 1 DR Cysteamine (delayed release cysteamine bitartrate) 25 4. 4. 2 GS 9450 (LB84451) 26 4. 4. 3 High-Dose Ursodesoxycholic acid (HD-UDCA) 27 4. 4. 4 Byetta (exenatide) 27 4. 4. 5 EGS21 (beta glucosylceramide formulation) 28 4. 5 Nonalcoholic Steatohepatitis Market – Clinical Pipeline by Mechanism of Action 30 4. 6 Nonalcoholic Steatohepatitis – Pipeline by Clinical Phases of Development 30 4. 6. 1 Nonalcoholic Steatohepatitis Therapeutics – Phase III Clinical Pipeline 31 4. 6. 2 Nonalcoholic Steatohepatitis Therapeutics – Phase II Clinical Pipeline 31 4. 6. 3 Nonalcoholic Steatohepatitis Therapeutics – Phase I Pipeline 32 4. 6. 4 Nonalcoholic Steatohepatitis Therapeutics – Preclinical Pipeline 32 4. 7 Discontinued Drug for Nonalcoholic Steatohepatitis Disease 32 4. 8 Key Takeaway 33

5 Nonalcoholic Steatohepatitis Market : Implications for Future Market Competition 34

6 Nonalcoholic Steatohepatitis Disease Market : Future Players in the Nonalcoholic Steatohepatitis Market 36 6. 1 Introduction 36 6. 2 Raptor Pharmaceuticals 36 6. 2. 1 Company Overview 36 6. 2. 2 Gastroenterology Disease Portfolio 37 6. 2. 3 Nonalcoholic Steatohepatitis Product Portfolio 37 6. 3 Gilead Sciences 38 6. 3. 1 Company Overview 38 6. 3. 2 Gastroenterology Disease Portfolio 39 6. 3. 3 Nonalcoholic Steatohepatitis Product Portfolio 39 6. 3. 4 Axcan Pharma 40 6. 3. 5 Company Overview 40 6. 3. 6 Gastroenterology Portfolio 41 6. 3. 7 Nonalcoholic Steatohepatitis Product Portfolio 42 6. 4 Eli Lilly and Company 43 6. 4. 1 Company Overview 43 6. 4. 2 Gastroenterology Portfolio 43 6. 4. 3 Nonalcoholic Steatohepatitis Product Portfolio 43 6. 5 Enzo Biochem 44 6. 5. 1 Company Overview 44 6. 5. 2 Gastroenterology Portfolio 46 6. 5. 3 Nonalcoholic Steatohepatitis Product Portfolio 46

7 Nonalcoholic Steatohepatitis Market : Appendix 48 7. 1 Market Definitions 48 7. 2 Abbreviations 48 7. 3 Research Methodology 49 7. 3. 1 Coverage 50 7. 3. 2 Secondary Research 50 7. 3. 3 Forecasting 50 7. 3. 4 Primary Research 53 7. 3. 5 Expert Panels 53 7. 4 Contact Us 53 7. 5 Disclaimer 53 7. 6 Sources 54

Pharmaceutical report offering, “Anemia – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global anemia market. The report identifies the key trends shaping and driving the global anemia market. The report also provides insight into the competitive landscape and the emerging players expected to bring a significant shift in the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global anemia market. Valued the anemia market in 2009 at $10. 4 billion, indicating a Compound Annula Growth Rate (CAGR) of 8. 5% between 2001 and 2009. The main driver for the growth of the anemia market is the rapid utilization of Erythropoietin Stimulating Agents (ESAs) such as Aranesp (darbepoeitin alfa), Procrit (epoetin alfa), Epogen (epoetin alfa) and Neorecormon (epoetin beta). These therapies are biological in nature and the annual cost of anemia therapy with these drugs ranges between $3,000 and $8,000. Evaluated the current competition in the anemia market as weak. Though iron deficiency anemia accounts for 40% of the total anemia population, none of the drugs indicated for iron deficiency anemia became a blockbuster. But, the majority of the ESAs that are indicated for selected types of anemia are blockbusters and currently dominate the market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts.

Scope

The scope of the report includes:

- Annualized global anemia market revenues data from 2001 to 2009, forecast forward for seven years to 2016.

- Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.

- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The first-in-class molecules are primarily Oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors, transforming growth factor (TGF)-beta inhibitors and transferrin receptor (TfR) targetters.

- Analysis of the current and future market competition in the global anemia market. Key future market players covered are Affymax, Pharmacosmos, Amgen Inc. , Hoffmann-La Roche, Chugai – Pharmaceutical Celgene Corporation, Hoffmann-La Roche, and Johnson and Johnson.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for future market associated with the anemia market. For More Information Please Click:http://www. aarkstore. com/reports/Anemia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-43090. html

Or Call Us: 919272852585

Visit Our Blog: http://blogs. aarkstore. com

The industry analysis specialist’s new report, “Irritable Bowel Syndrome – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global irritable bowel syndrome market. The report identifies the key trends shaping and driving the global irritable bowel syndrome market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global irritable bowel syndrome sector.   This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts.   Scope  The report provides information on the key driver and challenges of the global irritable bowel syndrome market. Its scope includes:  - Annualized global irritable bowel syndrome market revenues data from 2000 to 2009, forecast for seven years to 2016.  - Key geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan.  - Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include guanylate cyclase type C receptor agonists, serotonin receptors targets, corticotrophin releasing factor 1 receptor antagonists, NK receptor targets and 5-aminosalicylate targets.  - Analysis of the current and future market competition in the global irritable bowel syndrome market. Key market players covered include Sucampo Pharmaceuticals, Tillotts Pharma AG, GSK, Axcan Pharma, Salix Pharmaceuticals and Tioga Pharmaceuticals.  - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.  - Key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future irritable bowel syndrome market.   Reasons to buy  The report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to: - Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.  - Develop business strategies by understanding the trends shaping and driving the global irritable bowel syndrome market.  - Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global irritable bowel syndrome market in future.  - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.  - Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage.  - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.  - What’s the next huge thing in the global irritable bowel syndrome market landscape? – Identify, know and capitalize.

For more information, please contact :

http://www. aarkstore. com/reports/Irritable-Bowel-Syndrome-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40308. html

Pharmaceutical and healthcare report, “Hemophilia – Drug Pipeline Analysis and Market Forecasts to 2016″. The report is an essential source of information and analysis on the global hemophilia market. The report identifies the key trends shaping and driving the global hemophilia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hemophilia sector.  This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData’s analysis suggests that the global hemophilia market was valued at $6. 5 billion in 2009. This slow growth is primarily attributed to a low diagnosis rate and the high price of therapy. The safety and efficacy profiles of the existing therapies are moderate. The major treatments for hemophilia A include recombinant factor VIII drugs such as NovoSeven, Kogenate, Advate, ReFacto, Xyntha, Feiba and others for severe hemophilia cases. For mild to moderate hemophilia cases, DDAVP (desmopressin), which stimulates the release of factor VIII and also increases the level of proteins in the blood, is used. For hemophilia B, the most widely used branded drug is BeneFIX from Baxter Laboratories. BeneFIX is a clotting factor IX.  ScopeThe scope of the report includes:

Annualized global hemophilia market revenues data from 2001 to 2009, forecast for seven years to 2016.

Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.

Pipeline analysis data providing a split across different phases by the mechanism of action being developed and the emerging trends. The key classes of mechanism of action include substitution of coagulation factor VIII, increasing clotting factor VIII, plasma-derived FVIII.

Analysis of the current and future market competition in the global hemophilia market. The key market players covered are PTC Therapeutics, Recoly N. V. , Novo Nordisk.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the hemophilia market.

Reasons to buyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global haemophilia market.

Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global haemophilia market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

What’s the next huge thing in the global haemophilia market landscape? – Identify, know and capitalize

For more information on the report, kindly visit : http://www. visionshopsters. com/product/3183/Hemophilia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016. html———————————————-

The industry analysis specialist, has released a new report, “Ovarian Cancer – Drug Pipeline Analysis and Market Forecasts to 2016″. The report is an essential source of information and analysis on the global ovarian cancer market. The report identifies the key trends shaping and driving the global ovarian cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global ovarian cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts. Estimated the global ovarian cancer market to be valued at $697 million in 2009. It is forecast to grow by 13. 1% annually for the next seven years to reach $1,650 million by 2016. This growth is primarily attributed to high prescription rate of existing chemotherapy, strong pipeline and advancement of new targeted therapies. Analyzed that the global ovarian cancer market is moderately served with current product options and significant scope available to new entrants that would capture value from underserved segments. Designing curable products with high efficacy and safety profile is one of key challenges of this market and could provide significant market share for any company.   Analyzed that the global ovarian cancer market is increasingly becoming more competitive. Balancing the pipeline with the current marketed products and expectations of patients and physicians, the pipeline is considered to be strong. The unmet need in ovarian cancer market is high and if a company wants to capture this unmet need, it will need to overcome the prevailing product weaknesses and adverse effects. ScopeAnnualized global ovarian cancer market revenues data from 2001 to 2009, forecast forward 7 years to 2016. Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan. Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes topoisomerase inhibitor, drugs targeting DNA, vaccines, drugs targeting growth factor and growth factor receptors, folate receptor binder, kinase inhibitor, drugs targeting cytokines and combinations therapy. Analysis of the current and future market competition in the global ovarian cancer market. Key market players covered are F. Hoffmann-La Roche Ltd/Genentech, Inc. , Menarini Group, Novartis AG, Cell Therapeutics Inc. , Telik, Inc. and BioNumerik Pharmaceuticals Inc. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with ovarian cancer. For More Information Please Click :http://www. aarkstore. com/reports/Ovarian-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40533. html

The industry analysis specialist’s new report on the pharmaceutical and healthcare sector, “Type 2 Diabetes – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global type 2 diabetes market. The report identifies the key trends shaping and driving the global type 2 diabetes market, a key segment within the pharma industry. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global type 2 diabetes sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts. ScopeThe scope of the report includes: – Annualized global type-2 diabetes therapeutics market revenues data from 2001 to 2009, forecast forward for 7 years to 2016. – Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan. – Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. Key classes of mechanisms of action include SGLT-2 inhibitors, 11â HSD inhibitors, CCR2 antagonists, selective inhibitors of fructose 1,6-bisphosphatase, immune modulators, cortisol synthesis Inhibitors, interleukin-1â antagonists, gastrin-releasing peptide (GRP) receptor agonists, GPR 119 agonists,TLR-4 receptor agonists, FXR antagonists and antisense drugs targeting glucagon receptor. – Analysis of the current and future market competition in the global type-2 diabetes therapeutics market. Key future market players covered are Hoffmann-La Roche, Novo Nordisk, Merck & Co. , Novartis Ag, Sanofi-aventis, Eli Lilly & Company and GlaxoSmithKline. – Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. – Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with type-2 diabetes market. Reasons to buyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline. – Develop business strategies by understanding the trends shaping and driving the global type 2 diabetes market. – Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global type 2 diabetes market in future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. – What’s the next huge thing in the global type 2 diabetes market landscape? – Identify, know and capitalize. ” $2,000 $4,000 $6,000 GDHCPRT039 Pharmaceuticals and Healthcare Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action.   

For more information,please visit:

http://www. aarkstore. com/reports/Type-2-Diabetes-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40631. html

The industry analysis specialist’s new report on the pharmaceutical and healthcare sector, “Anti-Obesity – Drug Pipeline Analysis and Market Forecasts to 2016″ is an essential source of information and analysis on the global anti-obesity market. The report identifies the key trends shaping and driving the global anti- obesity market, a key segment within the pharma industry. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global anti-obesity sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts. ScopeThe scope of the report includes: – Annualized global anti-obesity market revenues data from 2001 to 2009, forecast forward for seven years to 2016. – Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan. – Pipeline analysis data providing a split across different phases, mechanisms of action being developed, and emerging trends. The pipeline candidates fall under the major categories such as appetite suppressants, calorie/stout absorption inhibitors, metabolism boosters and combination drugs. – Analysis of the current and future market competition in the global anti-obesity market. Key future market players covered are Orexigen Therapeutics, Arena Pharmaceuticals, and Vivus, Inc. which holds some of the most promising molecules that have demonstrated greater efficacy or safety or both. In addition, companies such as Alizyme Therapeutics, and NeuroSearch A/S are found to be the companies with noticeable Phase III molecules. – Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. – Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with anti-obesity. Reasons to buyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline. – Develop business strategies by understanding the trends shaping and driving the global anti-obesity market. – Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global anti-obesity market in future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. – What’s the next huge thing in the global anti-obesity market landscape? – Identify, know and capitalize. ” $2,000 $4,000 $6,000 GDHCPRT041 Pharmaceuticals and Healthcare Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action.

For more information,please visit:

http://www. aarkstore. com/reports/Anti-Obesity-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40635. html

Pharmaceutical and healthcare report,” Allergic Conjunctivitis – Drug Pipeline Analysis and Market Forecasts to 2016″ provides essential source of information and analysis on the global allergic conjunctivitis market. The report identifies the key trends shaping and driving the global allergic conjunctivitis market. The report also provides insights into the prevalent competitive landscape and the companies expected to significantly alter the market landscape. Most importantly, the report provides valuable insights into the pipeline products within the global allergic conjunctivitis sector.  This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData estimated the allergic conjunctivitis market in 2009 to be $1,069m. Allergic conjunctivitis is the most common type of eye allergy and is widely experienced by the global population. The incidence appears to be on the increase, possibly due to air pollution and allergens worldwide. The global allergic conjunctivitis market in 2009 primarily comprised of drug classes which included anti-histamines, mast cell stabilizers, dual action agents, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid products. The current allergic conjunctivitis market is dominated by brands, generics and off-mark formulations which have high patient affordability, and there is strong competition. The pipeline for allergic conjunctivitis lacks innovation and has 17 molecules in clinical development. Allergic conjunctivitis market has low unmet needs as the market is well served by the currently available different treatment options from different classes of therapiesScopeThe scope of the report includes:

Annualized global allergic conjunctivitis market revenues data from 2001 to 2009, forecast for seven years to 2016.

Geographies covered in this report are the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.

Pipeline analysis data providing a split across phases by mechanism of action, and the emerging trends. The key classes of mechanism of action include antihistamines/anti-allergic drugs which account for the largest share of the pipeline fallowed by immunosuppressants, NSAIDs, immunotherapy and PDE4 (Phosphodiesterase type 4) inhibitors.

Analysis of the current and future market competition in the global allergic conjunctivitis market. The key market players covered are Novagali Pharma SA, Fovea Pharmaceuticals SA, Cytos Biotechnology AG and Ono Pharmaceutical Co. Ltd.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future allergic conjunctivitis market.

Reasons to buyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global allergic conjunctivitis market.

Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global allergic conjunctivitis market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

What’s the next huge thing in the global allergic conjunctivitis market landscape? – Identify, know and capitalize.

For more information on the report, kindly visit : http://www. visionshopsters. com/product/3184/Allergic-Conjunctivitis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016. html———————————————-

WorldMarketStudy announces it Will Carry GlobalData’s Hemophilia – Drug Pipeline Analysis and Market Forecasts to 2016 June reports in its store. Browse complete report at http://www. worldmarketstudy. com/market-report/hemophilia-drug-pipeline-analysis-market-forecasts-2016-500. html GlobalData’s pharmaceutical and healthcare report, “Hemophilia – Drug Pipeline Analysis and Market Forecasts to 2016″. The report is an essential source of information and analysis on the global hemophilia market. The report identifies the key trends shaping and driving the global hemophilia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hemophilia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData’s analysis suggests that the global hemophilia market was valued at $6. 5 billion in 2009. This slow growth is primarily attributed to a low diagnosis rate and the high price of therapy. The safety and efficacy profiles of the existing therapies are moderate. The major treatments for hemophilia A include recombinant factor VIII drugs such as NovoSeven, Kogenate, Advate, ReFacto, Xyntha, Feiba and others for severe hemophilia cases. For mild to moderate hemophilia cases, DDAVP (desmopressin), which stimulates the release of factor VIII and also increases the level of proteins in the blood, is used. For hemophilia B, the most widely used branded drug is BeneFIX from Baxter Laboratories. BeneFIX is a clotting factor IX. ScopeThe scope of the report includes:Annualized global hemophilia market revenues data from 2001 to 2009, forecast for seven years to 2016. Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.  Pipeline analysis data providing a split across different phases by the mechanism of action being developed and the emerging trends. The key classes of mechanism of action include substitution of coagulation factor VIII, increasing clotting factor VIII, plasma-derived FVIII. Analysis of the current and future market competition in the global hemophilia market. The key market players covered are PTC Therapeutics, Recoly N. V. , Novo Nordisk. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the hemophilia market. Reasons to buyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the global haemophilia market. Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global haemophilia market in future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. What’s the next huge thing in the global haemophilia market landscape? – Identify, know and capitalize1 Table of contents 1. 1 List of Tables 1. 2 List of Figures 2 Hemophilia Market: Market Characterization 2. 1 Overview 2. 2 Hemophilia Therapeutics Market Size 2. 3 Hemophilia Therapeutics Market Forecast and CAGR 2. 4 Drivers and Barriers for the Hemophilia Therapeutics Market 2. 4. 1 Drivers for the Hemophilia Therapeutics Market 2. 4. 2 Barriers for the Hemophilia Therapeutics Market 2. 5 Opportunity and Unmet Need 2. 6 Key Takeaway 3 Hemophilia Therapeutics Market: Competitive Assessment 3. 1 Overview 3. 2 Strategic Competitor Assessment 3. 3 Product Profile for the Major Marketed Products in the Hemophilia Therapeutics Market 3. 3. 1 NovoSeven 3. 3. 2 Kogenate FS 3. 3. 3 Xyntha 3. 3. 4 Advate 3. 4 Key Takeaway 4 Hemophilia Therapeutics Market: Pipeline Assessment 4. 1 Overview 4. 2 Strategic Pipeline Assessment 4. 2. 1 Technology Trends Analytic Framework 4. 3 Hemophilia Therapeutics – Promising Drugs under Clinical Development 4. 4 Molecule Profile for Promising Drugs under Clinical Development 4. 4. 1 Ataluren (PTC124) 4. 4. 2 NecLip-rFVIIa (LongSeven) 4. 4. 3 rFVIII (Recombinant factor VIIa (N8)) 4. 5 Hemophilia Therapeutics Market – Clinical Pipeline by Mechanism of Action 4. 6 Hemophilia Therapeutics Pipeline – Pipeline by Clinical Phase of Development 4. 6. 1 Hemophilia Therapeutics – Phase III Clinical Pipeline 4. 6. 2 Hemophilia Therapeutics – Phase II Clinical Pipeline 4. 6. 3 Hemophilia Therapeutics – Phase I Clinical Pipeline 4. 6. 4 Hemophilia Therapeutics – Pre-clinical Pipeline 4. 7 Key Takeaway 5 Hemophilia Therapeutics Market: Implications for Future Market Competition 6 Hemophilia Therapeutics Market: Future Players in the Hemophilia Therapeutics Market 6. 1 Introduction 6. 2 PTC Therapeutics 6. 2. 1 Overview 6. 2. 2 Hemophilia Portfolio 6. 2. 3 Hemophilia Pipeline Portfolio 6. 2. 4 Ataluren (PTC124) 6. 3 Recoly N. V. 6. 3. 1 Overview 6. 3. 2 Hemophilia Portfolio 6. 3. 3 Hemophilia Pipeline Portfolio 6. 3. 4 NecLip-rFVIIa (LongSeven) 6. 4 Novo Nordisk 6. 4. 1 Overview 6. 4. 2 Hemophilia Portfolio 6. 4. 3 Hemophilia Pipeline Portfolio 6. 4. 4 rFVIII (Recombinant factor VIIa (N8)) 7 Hemophilia Therapeutics Market: Appendix 7. 1 Definitions 7. 2 Acronyms 7. 3 Research Methodology 7. 3. 1 Coverage 7. 3. 2 Secondary Research 7. 3. 3 Forecasting 7. 3. 4 Primary Research 7. 3. 5 Expert Panel Validation 7. 4 Contact Us 7. 5 Disclaimer 7. 6 Sources 1. 1 List of TablesTable 1: Hemophilia Therapeutics Market, Global, Revenues ($bn), 2001-2009 Table 2: Hemophilia Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2016Table 3: Major Marketed Products Comparison in the Hemophilia Therapeutics Market, 2010 Table 4: Hemophilia Therapeutics – Most Promising Drugs Under Clinical Development, 2010 Table 5: Hemophilia Therapeutics – Phase III Clinical Pipeline, 2010 Table 6: Hemophilia Therapeutics – Phase II Clinical Pipeline, 2010 Table 7: Hemophilia Therapeutics – Phase I Clinical Pipeline, 2010 Table 8: Hemophilia Therapeutics – Pre-Clinical Pipeline,  2010 Table 9: PTC Therapeutics, Inc. – Hemophilia Pipeline Products, 2010 Table 10: Recoly N. V. – Hemophilia Pipeline Products, 2010 Table 11: Novo Nordisk – Hemophilia Pipeline Products, 20101. 2 List of FiguresFigure 1: Hemophilia Therapeutics Market, Global, Revenues ($bn), 2001-2009 Figure 2: Hemophilia Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2016 Figure 3: Opportunity and Unmet Need in the Hemophilia Therapeutics Market, 2010 Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Hemophilia Therapeutics, 2010 Figure 5: Technology Trends Analytic Framework of the Hemophilia Pipeline, 2010 Figure 6: Technology Trends Analytic Framework of the Hemophilia Therapeutics  Pipeline – Description, 2010 Figure 7: Hemophilia Therapeutics Market, Global, Clinical Pipeline by Mechanism of Action (%), 2010 Figure 8: Hemophilia Therapeutics Pipeline by Phase of Clinical Development, 2010 Figure 9: Implications for Future Market Competition in the Hemophilia Therapeutics Market,  2010 Figure 10:Hemophilia Therapeutics Market – Clinical Pipeline by Company (No. of Molecules), 2010 Figure 11:GlobalData Methodology, 2010 Figure 12:GlobalData Market Forecasting Model, 2010View All Pharmaceuticals Market Reports http://www. worldmarketstudy. com/Pharmaceuticals-market-research-4. html

WorldMarketStudy announces it Will Carry GlobalData’s Pneumonia – Drug Pipeline Analysis and Market Forecasts to 2016 June reports in its store.

 

Browse complete report at http://www. worldmarketstudy. com/market-report/pneumonia-drug-pipeline-analysis-market-forecasts-2016-501. html

GlobalData’s pharmaceutical and healthcare report offering, “Pneumonia – Drug Pipeline Analysis and Market Forecasts to 2016″. is an essential source of information and analysis on the global pneumonia market. The report identifies the key trends shaping and driving the global pneumonia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global pneumonia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData’s analysis suggests that the global pneumonia market was worth $1. 4 billion in 2009. It is forecast to decline at a Compound Annual Growth Rate (CAGR) of 4. 3% for the next seven years to reach $1 billion by 2016. The projected decline rate is primarily attributable to the patent expiries of Levaquin, Avelox and Zyvox by the end of the forecast period. Increases in the treatment seeking population, the diagnosis population and the ever-increasing development of bacterial resistance to marketed antibiotics are expected to sustain the pneumonia market. Scope The scope of the report includes:

Reasons to buy The report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:

1 Table of Contents 1. 1 List of Tables 1. 2 List of Figures

2 Pnemonia Therapeutics Market: Market Characterization 2. 1 Overview 2. 2 Pneumonia Therapeutics Market Size 2. 3 Pneumonia Therapeutics Market Forecast and CAGR 2. 4 Drivers and Barriers for the Pneumonia Therapeutics Market 2. 4. 1 Drivers for the Pneumonia Therapeutics Market 2. 4. 2 Barriers for the Pneumonia Therapeutics Market 2. 5 Opportunity and Unmet Need 2. 6 Key Takeaway

3 Pneumonia Therapeutics Market: Competitive Assessment 3. 1 Overview 3. 2 Strategic Competitor Assessment 3. 3 Product Portfolio for Major Marketed Products in the Pneumonia Therapeutics Market 3. 3. 1 Zyvox (linezolid) 3. 3. 2 Zosyn (piperacillin and tazobactam) 3. 3. 3 Levaquin (levofloxacin) 3. 3. 4 Avelox (moxifloxacin) 3. 3. 5 Omnicef (cefdinir) 3. 3. 6 Tygacil (tigecycline) 3. 3. 7 Doribax (doripenem) 3. 4 Key Takeaway

4 Pneumonia Therapeutics Market: Pipeline Assessment 4. 1 Overview 4. 2 Strategic Pipeline Assessment 4. 2. 1 Technology Trends Analytical Framework 4. 3 Pneumonia Therapeutics – Promising Drugs under Clinical Development 4. 4 Molecule Profiles for Promising Drugs under Clinical Development 4. 4. 1 Ceftaroline 4. 4. 2 Ceftobiprole medocaril 4. 4. 3 Restanza (cethromycin) 4. 4. 4 Vibativ (telavancin) 4. 5 Pneumonia Therapeutics Market – Pipeline Assessment by Mechanism of Action 4. 6 Pneumonia Therapeutics Market – Pipeline Assessment by Phase of Clinical Development 4. 6. 1 Pneumonia Therapeutics – Phase III Clinical Pipeline 4. 6. 2 Pneumonia Therapeutics – Phase II Clinical Pipeline 4. 6. 3 Pneumonia Therapeutics – Phase I Clinical Pipeline 4. 6. 4 Pneumonia Therapeutics – Preclinical Pipeline 4. 6. 5 Pneumonia Therapeutics – Discovery Pipeline 4. 7 Discontinued/Suspended Drugs for Pneumonia 4. 8 Key Takeaway

5 Pneumonia Therapeutics Market: Implications for Future Market Competition

6 Pneumonia Therapeutics Market: Future Players in the Pneumonia Therapeutics Market 6. 1 Forest Laboratories, Inc. 6. 1. 1 Company Overview 6. 1. 2 Ceftaroline 6. 2 Basilea Pharmaceutica 6. 2. 1 Company Overview 6. 2. 2 Ceftobiprole medocaril 6. 3 Advanced Life Sciences 6. 3. 1 Company Overview 6. 3. 2 Restanza (cethromycin) 6. 4 Theravance, Inc. 6. 4. 1 Company Overview 6. 4. 2 Vibativ (telavancin)

7 Pneumonia Therapeutics Market: Appendix 7. 1 Definitions 7. 2 Acronyms 7. 3 Research Methodology 7. 4 Coverage 7. 5 Secondary Research 7. 6 Primary Research 7. 7 Models 7. 8 Forecasts 7. 9 Expert Panels 7. 10 Sources 7. 11 GlobalData Consulting 7. 12 Contact Us 7. 13 Disclaimer1. 1 List of Tables Table 1: Empirical Antimicrobial Therapy for Pneumonia, 2010 Table 2: Pneumonia Therapeutics Market, Global, Revenues ($m), 2001-2009 Table 3: Pneumonia Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 Table 4: Cure Rates of Zyvox in Nosocomial Pneumonia, 2010 Table 5: Cure Rates of Zyvox in Community-Bought Pneumonia due to MDRSP, 2010 Table 6: Pneumonia Therapeutics Market, Global, Most Promising Molecules under Clinical Development, May 2010 Table 7: Pneumonia Therapeutics Market, Global, Phase III Clinical Pipeline, 2010 Table 8: Pneumonia Therapeutics Market, Global, Phase II Clinical Pipeline, 2010 Table 9: Pneumonia Therapeutics Market, Global, Phase I Clinical Pipeline, 2010 Table 10: Pneumonia Therapeutics Market, Global, Preclinical Pipeline, 2010 Table 11: Pneumonia Therapeutics Market, Global, Discovery Pipeline, 2010 Table 12: Pneumonia Therapeutics Market, Global, List of Discontinued Drugs, 20101. 2 List of Figures Figure 1: Pneumonia Therapeutics Market, Global, Revenues ($m), 2001-2009 Figure 2: Pneumonia Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016 Figure 3: Pneumonia Therapeutics Market, Global, Opportunity and Unmet Need, 2010 Figure 4: Pneumonia Therapeutics Market, Global, Strategic Competitor Assessment of the Major Marketed Products, 2010 Figure 5: Pneumonia Therapeutics Pipeline, Global, Technology Trends Analytic Framework, 2010 Figure 6: Pneumonia Therapeutics Market, Global, Technology Trends Analytic Framework, Description—2010 Figure 7: Pneumonia Therapeutics Market, Global, Clinical Pipeline by Mechanism of Action, 2010 Figure 8: Pneumonia Therapeutics Market, Global, Clinical Pipeline, 2010 Figure 9: Pneumonia Therapeutics Market, Global, Implications for Future Market Competition, 2010 Figure 10: Pneumonia Therapeutics Market, Global, Clinical Pipeline by Company, 2010 Figure 11: GlobalData Methodology, 2010

View All Pharmaceuticals Market Reports http://www. worldmarketstudy. com/Pharmaceuticals-market-research-4. html

The industry analysis specialist, has released a new report, “Ovarian Cancer – Drug Pipeline Analysis and Market Forecasts to 2016″. The report is an essential source of information and analysis on the global ovarian cancer market. The report identifies the key trends shaping and driving the global ovarian cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global ovarian cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts. Estimated the global ovarian cancer market to be valued at $697 million in 2009. It is forecast to grow by 13. 1% annually for the next seven years to reach $1,650 million by 2016. This growth is primarily attributed to high prescription rate of existing chemotherapy, strong pipeline and advancement of new targeted therapies. Analyzed that the global ovarian cancer market is moderately served with current product options and significant scope available to new entrants that would capture value from underserved segments. Designing curable products with high efficacy and safety profile is one of key challenges of this market and could provide significant market share for any company.   Analyzed that the global ovarian cancer market is increasingly becoming more competitive. Balancing the pipeline with the current marketed products and expectations of patients and physicians, the pipeline is considered to be strong. The unmet need in ovarian cancer market is high and if a company wants to capture this unmet need, it will need to overcome the prevailing product weaknesses and adverse effects. ScopeThe scope of the report includes:

Annualized global ovarian cancer market revenues data from 2001 to 2009, forecast forward 7 years to 2016.

Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.

Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes topoisomerase inhibitor, drugs targeting DNA, vaccines, drugs targeting growth factor and growth factor receptors, folate receptor binder, kinase inhibitor, drugs targeting cytokines and combinations therapy.

Analysis of the current and future market competition in the global ovarian cancer market. Key market players covered are F. Hoffmann-La Roche Ltd/Genentech, Inc. , Menarini Group, Novartis AG, Cell Therapeutics Inc. , Telik, Inc. and BioNumerik Pharmaceuticals Inc.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with ovarian cancer.

Reasons to buyThe report will enhance your choice making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global ovarian cancer market.

Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global ovarian cancer market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolio and make effective counter-strategies to gain competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

What’s the next huge thing in the global ovarian cancer market landscape? – Identify, know and capitalize.

For more information,please visit:

http://www. aarkstore. com/reports/Ovarian-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016-40533. html